公开(公告)号：US20150252038A1

公开(公告)日：2015-09-10

申请号：US14603273

申请日：2015-01-22

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe ANDREZ ,  Paul Robert BICHLER ,  Chien-An CHEN ,  Sultan CHOWDHURY ,  Shannon Marie DECKER ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Ivan William HEMEON ,  Qi JIA ,  Jun LI ,  Zhiguo LIU ,  Daniel F. ORTWINE ,  Brian SAFINA ,  Daniel SUTHERLIN ,  Tao SHENG ,  Shaoyi SUN ,  Andrew D. WHITE ,  Michael Scott WILSON ,  Alla Yurevna ZENOVA ,  Jiuxiang ZHU

IPC: C07D453/02 ,  C07D205/04 ,  C07D401/06 ,  C07D403/12 ,  C07D401/12 ,  C07D211/42

CPC classification number: A61K31/445 ,  A61K31/337 ,  A61K31/397 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4412 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/495 ,  C07D205/04 ,  C07D207/12 ,  C07D211/22 ,  C07D211/32 ,  C07D211/42 ,  C07D211/54 ,  C07D211/60 ,  C07D233/68 ,  C07D237/08 ,  C07D241/04 ,  C07D265/30 ,  C07D305/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D453/02 ,  C07D487/08 ,  C07F7/0812

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compactions.

Abstract translation: 本发明提供具有通式I的化合物及其药学上可接受的盐，其中变量RA，RAA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4，R5和RN 具有本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。

公开(公告)号：US20130252962A1

公开(公告)日：2013-09-26

申请号：US13787558

申请日：2013-03-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail CHAFEEV ,  Sultan CHOWDHURY ,  Lauren FRASER ,  Jianmin FU ,  Jonathan LANGILLE ,  Shifeng LIU ,  Jianyu SUN ,  Shaoyi SUN ,  Serguei SVIRIDOV ,  Mark WOOD ,  Alla Yurevna ZENOVA ,  Qi JIA ,  Jean-Jacques Alexandre CADIEUX ,  Simon J. GAUTHIER ,  Amy Frances DOUGLAS ,  Tom HSIEH ,  Nagasree CHAKKA ,  Zoran CIKOJEVIC

IPC: C07D491/107 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D491/20

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.